Stock analysts at Deutsche Bank initiated coverage on shares of DENTSPLY SIRONA (NASDAQ:XRAY) in a note issued to investors on Friday. The firm set a “buy” rating and a $81.00 price target on the medical instruments supplier’s stock. Deutsche Bank’s target price suggests a potential upside of 24.81% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. TheStreet raised shares of DENTSPLY SIRONA from a “c” rating to a “b-” rating in a report on Friday, November 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $68.00 price objective on shares of DENTSPLY SIRONA in a report on Tuesday, October 3rd. Jefferies Group decreased their price objective on shares of DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating for the company in a report on Wednesday, August 23rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $66.00 price objective (down previously from $70.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. Finally, Robert W. Baird set a $63.00 price objective on shares of DENTSPLY SIRONA and gave the stock a “buy” rating in a report on Thursday, October 19th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. DENTSPLY SIRONA presently has an average rating of “Buy” and an average target price of $68.83.

DENTSPLY SIRONA (NASDAQ XRAY) opened at $64.90 on Friday. The company has a market cap of $14,906.43, a price-to-earnings ratio of 25.86, a price-to-earnings-growth ratio of 2.57 and a beta of 1.31. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. DENTSPLY SIRONA has a 1-year low of $52.53 and a 1-year high of $68.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Friday, November 3rd. The medical instruments supplier reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $978.99 million. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.66 earnings per share. equities analysts forecast that DENTSPLY SIRONA will post 2.65 EPS for the current year.

In related news, CFO Nicholas W. Alexos bought 50,000 shares of the business’s stock in a transaction on Monday, November 13th. The shares were bought at an average cost of $65.85 per share, for a total transaction of $3,292,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Francis J. Lunger sold 8,900 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $65.90, for a total value of $586,510.00. The disclosure for this sale can be found here. Company insiders own 1.99% of the company’s stock.

A number of hedge funds have recently bought and sold shares of XRAY. Veritas Asset Management LLP raised its stake in shares of DENTSPLY SIRONA by 2.6% during the second quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock valued at $402,083,000 after purchasing an additional 157,616 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in shares of DENTSPLY SIRONA by 78.7% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 11,886 shares of the medical instruments supplier’s stock valued at $771,000 after purchasing an additional 5,236 shares in the last quarter. Royce & Associates LP raised its stake in shares of DENTSPLY SIRONA by 23.4% during the second quarter. Royce & Associates LP now owns 126,650 shares of the medical instruments supplier’s stock valued at $8,212,000 after purchasing an additional 24,000 shares in the last quarter. Delta Lloyd Asset Management N.V. bought a new stake in shares of DENTSPLY SIRONA during the second quarter valued at about $15,624,000. Finally, Capital Fund Management S.A. raised its stake in shares of DENTSPLY SIRONA by 204.0% during the second quarter. Capital Fund Management S.A. now owns 88,170 shares of the medical instruments supplier’s stock valued at $5,717,000 after purchasing an additional 59,170 shares in the last quarter. Institutional investors own 96.58% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “DENTSPLY SIRONA (XRAY) Now Covered by Deutsche Bank” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/10/dentsply-sirona-xray-now-covered-by-deutsche-bank.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Stock Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related stocks with our FREE daily email newsletter.